Results 131 to 140 of about 57,195 (184)

TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions

Hematological Oncology, Volume 43, Issue 4, July 2025.
ABSTRACT TP53‐mutated acute myeloid leukemia (AML) remains one of the most treatment‐resistant hematologic malignancies, with poor overall survival despite advancements in therapeutic strategies. The loss of functional p53 compromises DNA repair, apoptosis, and genomic stability, rendering both conventional and novel therapies largely ineffective. This
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Caterina Labanca, Giulio Caridà, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito, Massimo Gentile   +11 more
wiley   +1 more source

CDK4/6 inhibitor in combination with aromatase inhibitor effective in metastatic hidradenocarcinoma

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Valerie Glatzel, Dirk Tomsitz, Michaela Maurer, Simone Schneider, Stefan Brunner, Nadia Harbeck, Lucie Heinzerling   +6 more
wiley   +1 more source

Exposure to per‐ and polyfluoroalkyl substances in residential settled dust and risk of childhood acute lymphoblastic leukemia

International Journal of Cancer, Volume 157, Issue 1, Page 103-115, 1 July 2025.
What's new? Because of widespread use and resistance to degradation, per‐ and polyfluoroalkyl substances (PFAS) are ubiquitous in the environment. For young children, owing in part to crawling and hand‐to‐mouth behaviors, PFAS exposure is unique. Here, the authors investigated the risk of childhood leukemia in relation to PFAS found in settled dust ...
Catherine Metayer, Libby M. Morimoto, Veronica M. Vieira, Krystal J. Godri Pollitt, Scott M. Bartell, Luann Wong, Thomas M. Young   +6 more
wiley   +1 more source

Late Mortality Among Survivors of Childhood Cancer in Canada: A Retrospective Cohort Study

Pediatric Blood &Cancer, Volume 72, Issue 7, July 2025.
ABSTRACT Background Children with cancer face an increased risk of complications and death beyond the 5‐year survival mark. National surveillance efforts facilitate the systematic tracking of long‐term health outcomes, including treatment‐related complications and late mortality, among childhood cancer survivors.
Katherine McKenzie, Brianna Belanger, Shruti Parshad, Lin Xie, Vera Grywacheski, Miranda Fidler‐Benaoudia   +5 more
wiley   +1 more source

Twenty Years of the Paediatric Radiation Oncology Society

Pediatric Blood &Cancer, Volume 72, Issue 7, July 2025.
ABSTRACT In 2005, the Paediatric Radiation Oncology Society (PROS), a multi‐professional association to promote radiotherapy for children and young people, was created. Its mission has been to educate those involved in this field, and to improve the standards of radiation oncology care for children, adolescents, and young adults across the globe, not ...
Mark N. Gaze, Guillaume Beldjoudi, Christian Carrie, Carolyn Freeman, Daniel J. Indelicato, Rolf‐Dieter Kortmann, Ingrid Kristensen, Anne Laprie, Yasmin Lassen, Anita Mahajan, Karen J. Marcus, Pauline Njoki Njiraini, Jeannette Parkes, Arnold C. Paulino, Bilal Mazhar Qureshi, Beatriz García Robles, Klaus Seiersen, Beate Timmermann, Natia Esiashvili   +18 more
wiley   +1 more source

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives

American Journal of Hematology, Volume 100, Issue S4, Page 30-50, June 2025.
ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley   +1 more source

Retinoblastoma: The Evidence Does Matter

Cellular Oncology, 2009
Nadia L. Prigoda-Leea, Diane Rushlowa, Beata Piovesan, Katherine Zhang, Helen Dimaras, Sanja Pajovic, Brenda L. Galliea   +6 more
doaj   +1 more source

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

Cancer Innovation, Volume 4, Issue 3, June 2025.
ABSTRACT Background The phosphoinositide 3‐kinase (PI3K)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays a critical role in breast cancer pathogenesis and progression, and is closely linked with resistance to endocrine therapy in advanced breast cancer.
The Breast Cancer Expert Committee of the National Quality Control Center for Cancer, The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center, The Society of Clinical Research on Oncology Medications of the China Anti‐Cancer Association, The Society of Onco‐Pathology of the China Anti‐Cancer Association   +3 more
wiley   +1 more source

Phosphorylation State of RB Modulates Ferroptotic Sensitivity

Cell Biochemistry and Function, Volume 43, Issue 6, June 2025.
ABSTRACT Tumor suppressor RB is a central regulator of cell cycle progression. By binding to E2F transcription factors, RB can inhibit transcription of E2F target genes to cause cell cycle arrest. Cyclin dependent kinases (CDK) regulate the interaction of RB/E2F by phosphorylating RB at multiple sites.
Nishanth Kuganesan, Samkeliso Dlamini, L. M. Viranga Tillekeratne, William R. Taylor   +3 more
wiley   +1 more source

Risk of childhood brain tumors after exposure to CT radiation: A nationwide population‐based case–control study in Finland

International Journal of Cancer, Volume 156, Issue 11, Page 2148-2157, 1 June 2025.
What's new? This population‐based case‐control study quantifies the risk of childhood brain tumors following exposure to radiation from computed tomography scans in Finland. Leveraging comprehensive nationwide cancer and computed tomography data and addressing key limitations in previous research, including reverse causation and confounding by ...
Jad Abuhamed, Atte Nikkilä, Jani Raitanen, Olli Lohi, Anssi Auvinen   +4 more
wiley   +1 more source